Skip to main content
Positive results reported by Trovagene on onvansertib midstage trial

Data from Trovagene's Phase Ib/II clinical trial assessing onvansertib in patients with relapsed or refractory acute myeloid leukemia showed the drug was safe and effective, according to a presentation made at the 2019 European Society for Medical Oncology Conference. Trovagene plans to enroll 32 patients with AML in the midstage trial to evaluate onvansertib combined with decitabine in participants who complete at least a single treatment cycle.

Full Story: